Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 5
2005 3
2006 7
2007 5
2008 3
2009 2
2010 4
2011 10
2012 12
2013 7
2014 13
2015 16
2016 14
2017 14
2018 10
2019 9
2020 20
2021 13
2022 11
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
RESULTS: A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). ...The cumulative probability …
RESULTS: A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lublin F, et al. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Lancet. 2016. PMID: 26827074 Free article. Clinical Trial.
We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis. ...FINDINGS: 970 patients were randomly assigned between Sept 3, 2008, and Aug 30, 2011 (147 to fingolimod 1.25 mg and 133 to placebo in cohort 1; 336 to fi
We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis. ...FINDINGS: 970 patients …
Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD009371. doi: 10.1002/14651858.CD009371.pub2. Cochrane Database Syst Rev. 2016. PMID: 27091121 Free PMC article. Review.
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). ...The risk of fingolimod discontinuation was significantly higher compared to placebo for the dose 1.25 mg at 24 months (RR …
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosi …
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
Yang T, Tian X, Chen CY, Ma LY, Zhou S, Li M, Wu Y, Zhou Y, Cui YM. Yang T, et al. Br J Clin Pharmacol. 2020 Apr;86(4):637-645. doi: 10.1111/bcp.14198. Epub 2020 Feb 8. Br J Clin Pharmacol. 2020. PMID: 31869429 Free PMC article. Review.
Fingolimod also exhibited a favorable performance on other magnetic resonance imaging outcomes and improved the quality of life in patients. ...CONCLUSIONS: Fingolimod may offer benefits for RMS patients and presents an acceptable safety profile....
Fingolimod also exhibited a favorable performance on other magnetic resonance imaging outcomes and improved the quality of life in pa
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B, Ross AP, Tobias K. Singer B, et al. Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16. Int J Clin Pract. 2011. PMID: 21679286 Review.

In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001). Risk of disability progression, confirmed at 3 months, was also reduced by 30% over the 2-year study period with fingolimod vs. placebo (p = 0.0

In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001). Risk of dis

Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.
Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M. Askari M, et al. Mult Scler Relat Disord. 2022 Mar;59:103680. doi: 10.1016/j.msard.2022.103680. Epub 2022 Feb 9. Mult Scler Relat Disord. 2022. PMID: 35176641 Review.
BACKGROUND: Fingolimod is a sphingosine-1-phosphate-receptor modulator that is used for the relapsing form of MS. There are controversial reports regarding the incidence of cancer in patients with MS who were treated with fingolimod. Therefore, we designed this syst …
BACKGROUND: Fingolimod is a sphingosine-1-phosphate-receptor modulator that is used for the relapsing form of MS. There are controver …
Prognostic significance of neurofilament light in Fingolimod therapy for Multiple Sclerosis: A systemic review and meta-analysis based on randomized control trials.
Ashkar A, Baig MMA, Arif A, Ali MM, Yousuf F, Ashkar R. Ashkar A, et al. Mult Scler Relat Disord. 2023 Jan;69:104416. doi: 10.1016/j.msard.2022.104416. Epub 2022 Nov 17. Mult Scler Relat Disord. 2023. PMID: 36495843 Review.
Moreover, effect of Fingolimod on NfL levels was analysed qualitatively. RESULTS: Five Randomized Controlled Trials were used in the study. ...CONCLUSION: The results of our meta-analysis and systematic review demonstrated statistically significant effect of NfL as a progn …
Moreover, effect of Fingolimod on NfL levels was analysed qualitatively. RESULTS: Five Randomized Controlled Trials were used in the …
[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Aktas O, Ingwersen J, Kieseier B, Küry P, Hohlfeld R, Hartung HP. Aktas O, et al. Nervenarzt. 2011 Feb;82(2):215-25. doi: 10.1007/s00115-010-3075-8. Nervenarzt. 2011. PMID: 20842337 Review. German.
In this article the recent clinical data on novel therapy of relapsing multiple sclerosis with oral fingolimod (FTY720), lead substance of the recently described class of sphingosine-1-phosphate (S1P) receptor modulators are reviewed. ...Furthermore, data from experimental …
In this article the recent clinical data on novel therapy of relapsing multiple sclerosis with oral fingolimod (FTY720), lead substan …
The effect of Fingolimod on patients with moderate to severe COVID-19.
Teymouri S, Pourbayram Kaleybar S, Hejazian SS, Hejazian SM, Ansarin K, Ardalan M, Zununi Vahed S. Teymouri S, et al. Pharmacol Res Perspect. 2023 Feb;11(1):e01039. doi: 10.1002/prp2.1039. Pharmacol Res Perspect. 2023. PMID: 36567519 Free PMC article. Clinical Trial.
However, no significant differences were found regarding the intubation or mortality rate between the groups (p > .05). Fingolimod could significantly reduce the re-admission rate after hospitalization with COVID-19. Fingolimod may not enhance patients' outcomes …
However, no significant differences were found regarding the intubation or mortality rate between the groups (p > .05). Fingolimod
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, Foschi M, Filippini G, Tramacere I, Baldin E, Nonino F. Gonzalez-Lorenzo M, et al. Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3. Cochrane Database Syst Rev. 2024. PMID: 38174776 Free PMC article. Review.
Natalizumab results in a large reduction of people with relapses at 12 months (RR 0.52, 95% CI 0.43 to 0.63; high-certainty evidence). Fingolimod (RR 0.48, 95% CI 0.39 to 0.57; moderate-certainty evidence), daclizumab (RR 0.55, 95% CI 0.42 to 0.73; moderate-certainty evide …
Natalizumab results in a large reduction of people with relapses at 12 months (RR 0.52, 95% CI 0.43 to 0.63; high-certainty evidence). Fi
165 results